Photoredox catalysis has emerged an attractive tool for medicinal chemistry, streamlining both targeted drug synthesis and late-stage molecular editing. Research in the Bloom group seeks to harness this multifarious platform to address key challenges at the interface of synthetic chemistry and biology.
Specifically, Bloom's group is interested in the use of photoredox catalysis for the derivatization of drug-like molecules to enhance their therapeutic efficacy. Along these lines, they focus on the selective incorporation of fluorine atoms into biomedically relevant scaffolds, the controlled cyclization of linear peptides to afford potent cyclic analogues, and the incorporation of alternative functionalities which enhance both physiochemical and pharmacokinetic properties of target molecules.
Finally, the group aims to assess and understand these molecular perturbations towards the development and rational design of lead compounds for the treatment of disease.